NEWS

(November 8 2016) AdAlta licenses Alzheimer’s disease-specific shark antibodies to Crossbeta Biosciences for therapeutic and diagnostic development. Crossbeta has been granted an exclusive license to three beta-amyloid oligomer (AßO)-specific shark antibodies, identified under the collaboration signed between AdAlta and Crossbeta in December 2013. These shark antibodies are considered to have immediate and highly disease-specific potential for the diagnosis and treatment of Alzheimer’s disease. The three licensed anti-AßO antibodies do not recognize or bind to the monomer and fibrils of the beta-amyloid protein. Read the full press release (pdf).

 

(June 30 2016) Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), announced today an agreement with the Dutch biotech company Crossbeta Biosciences B.V. in order to utilize Crossbeta’s proprietary technology in support of Probiodrug’s  biomarker development activities. Read the full press release (pdf).

 

(June 6 2016) Crossbeta was featured in the 'hersenen' ('brain') supplement of national newspaper De Telegraaf. See the article here (pdf; Crossbeta on page 6).

 

(April 18 2016) Crossbeta Biosciences today announced that it received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) in the amount of USD 425,000 for the development of an alpha-synuclein oligomer-specific antibody. Such oligomer-specific antibodies will add great value to Parkinson’s disease research, as they hold significant potential for the development of novel, disease-specific biomarker tools, an area that currently forms a bottleneck in Parkinson’s disease diagnosis and drug development. Furthermore, alpha-synuclein oligomer-specific antibodies may be developed into Parkinson therapeutics themselves. Read the full press release (pdf)

 

(October 5 2015) Crossbeta Biosciences and Servier today announced their collaboration in several research projects involving the use of Crossbeta’s technology for generating stable oligomers. Crossbeta and Servier will jointly develop multiple oligomer types that will be used by Servier for its preclinical research programs in CNS. Read the full press release (pdf)

 

(July 2015) Crossbeta completes financing round and secures Innovation Grant. Crossbeta Biosciences today announced that it has completed a round of internal financing. In addition, the company secured another Innovation Grant from the Dutch government agency RVO for the further development of Crossbeta’s platform technology and stable oligomers in the field of Alzheimer’s, Parkinson’s, ALS and Huntington’s disease. Read the full release (pdf)

 

 

enthusiastic and motivated students with a background in

Life Sciences; Analytical-,or Bio-Chemistry

CROSSBETA

Stabilizing oligomers and targeting toxic oligomers is the basis for Crossbeta's  oligomer drug discovery platforms which are accessible for partnering in therapeutic areas such as Alzheimer's, Parkinson's, Huntington and Diabetes Type 2.

 

In our Alzheimer program we have recently completed a high throughput screening campaign with 100,000 compounds resulting in the selection of 5 hit classes with >50%  neutralizing effect on oligomer-induced neurotoxicity.

 

Stable oligomers can also be used as reference in biomarker assays.

 

Where to meet us

BioEurope 2016 -  November 7-9 in Cologne, Germany

 

 

 

Copyright © 2013 | Disclaimer | Sitemap | Contact Phone: +31 30 253 8823 | Mail: info@crossbeta.com